LEUKEMIAS

Working in a laboratory at the National Institutes of Health, Benjamin W. Purow, MD, became the first researcher to demonstrate that the Notch pathway plays a role in gliomas.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.

While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.

Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.

Acute myeloid leukemia (AML), the most common acute form of leukemia in adults, is potentially driven by at least one genetic mutation in nearly all cases.

Implementation of a pharmacist-led glycemic control team was associated with improved glycemic control and utilization outcomes in a population of noncritically ill surgical patients.

Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.